Erectile dysfunction (ED) is one of the extrahepatic manifestations
of hepatitis C virus infection that greatly affects patients’ quality of life. Unfortunately,
some of the drugs used for HCV treatment may have a negative impact on the patient’s erectile
function, such as the pegylated interferon. Currently, with the introduction of direct-acting antiviral
drugs, there is scarce data in the literature about its potential impact on erectile function. In these
settings, we aimed to assess the impact of sofosbuvir-based therapy on male erectile function.
Methods: This prospective interventional study was carried out in Benha University hospitals between
January 2019 and May 2020. The study included all consecutive HCV patients with simultaneous
ED coming to the hepatology outpatient clinic. Patients were divided into a study group who
received sofosbuvir-based therapy (group A) or a control group who received silymarin therapy
(group B). The International Index of Erectile Function-5 (IIEF-5) was used for the assessment of
erectile function at different time points (pretreatment, 6 months, and 12 months after treatment).
Different variables in both groups have been statistically analyzed.
Results: Overall, 75 patients who received sofosbuvir-based therapy and a control group (n = 35)
matched for age and pretreatment variables (Child–Turcotte–Pugh score and Fibrosis‐4 score).
There was no significant difference between both groups in the pretreatment data. On the other
hand, the posttreatment IIEF-5 was significantly higher in the sofosbuvir arm compared to the silymarin
arm both at six months (p |
